Emma Guttman-Yassky
Icahn School of Medicine at Mount Sinai · Mt. Sinai Hospital Department of Dermatology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emma Guttman-Yassky as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05866562 · Dupilumab in the Treatment of Pediatric Alopecia AreataIcahn School of Medicine at Mount Sinai · recruiting · Alopecia Areata · principal investigator
- Ph2NCT05551793 · Regeneron AA Multicenter (Dupilumab)Emma Guttman · recruiting · Alopecia Areata · principal investigator
- Ph2NCT05549934 · Ritlecitinib for Cicatricial AlopeciaEmma Guttman · completed · Cicatricial Alopecia · principal investigator
- Ph2NCT03041038 · The Efficacy and Safety of Secukinumab in Patients With IchthyosesNorthwestern University · completed · Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:49 UTC. The ranking covers the 200 most relevant of 92 PubMed records, and a shared surname and initials can bring in a namesake. All 92 on PubMed
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.N Engl J Med · 20161,639 citationsRCR 66.2
- Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.N Engl J Med · 20141,130 citationsRCR 38.3
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.J Allergy Clin Immunol · 2019576 citationsRCR 29.1
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).Br J Dermatol · 2021513 citationsRCR 38.5
- 476 citationsRCR 33.7
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.JAMA Dermatol · 2020421 citationsRCR 27.1
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.J Allergy Clin Immunol · 2014388 citationsRCR 13.5
- Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.J Allergy Clin Immunol · 2019314 citationsRCR 15.4
- Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.J Allergy Clin Immunol · 2020296 citationsRCR 16.9
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.N Engl J Med · 2023287 citationsRCR 36.7